☆ 4.4 Article

Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients

CURRENT ONCOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Urology & Nephrology

Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study

Cristina Masini et al.

Summary: This study evaluated the efficacy and safety of stereotactic body radiotherapy (SBRT) in combination with nivolumab in second- and third-line metastatic renal cell carcinoma (mRCC) patients. The results showed that the combination treatment did not provide additional clinical benefits but was safe and showed a good response in the irradiated lesions.

EUROPEAN UROLOGY (2022)

Add to Collection

Article Urology & Nephrology

Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial

Shankar Siva et al.

Summary: The RAPPORT trial investigated the combination of high-dose precision radiotherapy and a short course of immunotherapy in patients with low-volume metastatic kidney cancer. The results showed that this treatment regimen was well tolerated, with excellent cancer control in known disease sites, and a proportion of patients were free from cancer relapse in the longer term. These findings are encouraging and warrant further investigation.

EUROPEAN UROLOGY (2022)

Add to Collection

Article Oncology

A Story of Hypofractionation and the Table on the Wall

Robert Timmerman

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

Add to Collection

Article Oncology

Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer

Raquibul Hannan et al.

Summary: SAbR treatment can extend the duration of ongoing systemic therapy for mRCC patients with limited progression without compromising quality of life.

EUROPEAN UROLOGY ONCOLOGY (2022)

Add to Collection

Review Oncology

Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review

Gianluca Ingrosso et al.

Summary: In this systematic review and meta-analysis, SBRT combined with drug therapy in mRCC patients was found to be safe and did not increase drug-related adverse events. Promising clinical outcomes in terms of local control and overall survival were also observed with this approach.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

Add to Collection

Article Oncology

Stereotactic Body Radiotherapy of a Solitary Metachronous Sphenoid Metastasis from Renal Cell Cancer: A Case Report

Charles Marchand Crety et al.

Summary: Here we report a rare case of solitary sphenoid metastasis from papillary renal cell cancer, which presented 8 months after surgery and showed complete regression after receiving radiation therapy.

CASE REPORTS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors

Liru He et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2020)

Add to Collection

Article Oncology

Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC).

Hans J. Hammers et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Urology & Nephrology

Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma

Ciro Franzese et al.

JOURNAL OF UROLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

David A. Palma et al.

LANCET (2019)

Add to Collection

Article Oncology

Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

David A. Palma et al.

BMC CANCER (2019)

Add to Collection

Article Oncology

Time to abandon single-site irradiation for inducing abscopal effects

Eric D. Brooks et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

Add to Collection

Review Urology & Nephrology

The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Rohann J. M. Correa et al.

EUROPEAN UROLOGY FOCUS (2019)

Add to Collection

Article Oncology

Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies

Nicholas G. Zaorsky et al.

EUROPEAN UROLOGY ONCOLOGY (2019)

Add to Collection

Article Oncology

Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group

Emmanuel Meyer et al.

EUROPEAN JOURNAL OF CANCER (2018)

Add to Collection

Article Oncology

Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014

M. Stenman et al.

RADIOTHERAPY AND ONCOLOGY (2018)

Add to Collection

Article Biotechnology & Applied Microbiology

Partial stereotactic ablative boost radiotherapy in bulky non-small cell lung cancer: a retrospective study

Yun Bai et al.

ONCOTARGETS AND THERAPY (2018)

Add to Collection

Review Oncology

Stereotactic body radiation therapy (SBRT) on renal cell carcinoma, an overview of technical aspects, biological rationale and current literature

G. Francolini et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

Targeting renal cell carcinoma with a HIF-2 antagonist

Wenfang Chen et al.

NATURE (2016)

Add to Collection

Article Oncology

Stereotactic Body Radiotherapy for the Treatment of Oligometastatic Renal Cell Carcinoma

Mark C. Ranck et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)

Add to Collection

Article Oncology

TUMOR CONTROL OUTCOMES AFTER HYPOFRACTIONATED AND SINGLE-DOSE STEREOTACTIC IMAGE-GUIDED INTENSITY-MODULATED RADIOTHERAPY FOR EXTRACRANIAL METASTASES FROM RENAL CELL CARCINOMA

Michael J. Zelefsky et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)

Add to Collection

Article Medicine, General & Internal

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Marco Gerlinger et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Editorial Material Oncology

QUANTITATIVE ANALYSES OF NORMAL TISSUE EFFECTS IN THE CLINIC (QUANTEC): AN INTRODUCTION TO THE SCIENTIFIC ISSUES

Soren M. Bentzen et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Stereotactic body radiation therapy: The report of AAPM Task Group 101

Stanley H. Benedict et al.

MEDICAL PHYSICS (2010)

Add to Collection

Article Surgery

Renal radiosurgery: Initial clinical experience with histological evaluation

Lee E. Ponsky et al.

SURGICAL INNOVATION (2007)

Add to Collection

Review Urology & Nephrology

Renal cell carcinoma 2005: New frontiers in staging, prognostication and targeted molecular therapy

JS Lam et al.

JOURNAL OF UROLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.